<?xml version="1.0" encoding="UTF-8"?>
<ref id="B109">
 <label>109.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Oh</surname>
    <given-names>J</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Barve</surname>
    <given-names>M</given-names>
   </name>
   <span xml:space="preserve" class="x" xmlns="http://www.w3.org/1999/xhtml">, </span>
   <name name-style="western">
    <surname>Matthews</surname>
    <given-names>CM</given-names>
   </name>
  </person-group>
  <etal/>
  <article-title>Phase II study of Vigil(R) DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer</article-title>. 
  <source>Gynecol. Oncol.</source>
  <volume>143</volume>(
  <issue>3</issue>), 
  <fpage>504</fpage>â€“
  <lpage>510</lpage> (
  <year>2016</year>).
  <pub-id pub-id-type="pmid">27678295</pub-id>
 </mixed-citation>
</ref>
